首页 > 最新文献

Biochemia medica最新文献

英文 中文
Serum concentration of ferroportin in women of reproductive age. 育龄妇女血清中的铁蛋白浓度。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030701
Ana Ćuk, Lada Rumora, Ivanka Mikulić, Nikolina Penava, Ivona Cvetković, Ante Pušić, Vinka Mikulić, Kristina Ljubić, Vajdana Tomić

Introduction: Ferroportin (Fpn) is the only known iron exporter and plays an essential role in iron homeostasis. Serum concentrations of Fpn in health and/or diseased states are still mostly unknown. Therefore, the aim of this study was to determine the concentration of Fpn in the serum of women of reproductive age (WRA) for the first time, and to establish whether there is a difference in the concentration of Fpn according to ferritin status.

Materials and methods: This research included 100 WRA (18-45 years, C-reactive protein (CRP) < 5 mg/L, hemoglobin > 120 g/L). Serum Fpn was measured using Enzyme Linked Immunosorbent Assay (ELISA) method on the analyzer EZ Read 800 Plus (Biochrom, Cambridge, UK). Reference interval was calculated using the robust method.

Results: The median concentration of Fpn in the whole study group was 9.74 (5.84-15.69) µg/L. The subgroup with ferritin concentration > 15 µg/L had a median Fpn concentration 15.21 (10.34-21.93) µg/L, which significantly differed from Fpn concentration in the subgroup with ferritin concentration ≤ 15 µg/L (5.93 (4.84-8.36) µg/L, P < 0.001). The reference limits for the Fpn were 2.26-29.81 µg/L with 90% confidence intervals (CI) of 1.78 to 2.83 and 25.37 to 34.33, respectively.

Conclusions: The proposed reference interval could help in the future research on iron homeostasis both in physiological conditions and in various disorders, because this is the first study that measured Fpn concentration in a certain gender and age group of a healthy population.

简介铁蛋白(Fpn)是唯一已知的铁输出因子,在铁平衡中发挥着重要作用。健康和/或疾病状态下血清中 Fpn 的浓度大多仍不清楚。因此,本研究旨在首次测定育龄妇女(WRA)血清中 Fpn 的浓度,并确定铁蛋白状态是否会导致 Fpn 浓度的差异:研究对象包括 100 名育龄妇女(18-45 岁,C 反应蛋白 (CRP) < 5 mg/L,血红蛋白 > 120 g/L)。在 EZ Read 800 Plus(Biochrom,英国剑桥)分析仪上使用酶联免疫吸附试验(ELISA)法测定血清 Fpn。采用稳健法计算参考区间:整个研究组的铁蛋白浓度中位数为 9.74 (5.84-15.69) µg/L。铁蛋白浓度大于 15 µg/L 的亚组的 Fpn 中位浓度为 15.21 (10.34-21.93) µg/L,与铁蛋白浓度小于 15 µg/L 的亚组的 Fpn 中位浓度有显著差异(5.93 (4.84-8.36) µg/L,P < 0.001)。Fpn的参考限值为2.26-29.81 µg/L,90%置信区间(CI)分别为1.78-2.83和25.37-34.33:由于这是首次在特定性别和年龄组的健康人群中测量 Fpn 浓度的研究,因此所提出的参考区间有助于今后对生理条件下和各种疾病中铁稳态的研究。
{"title":"Serum concentration of ferroportin in women of reproductive age.","authors":"Ana Ćuk, Lada Rumora, Ivanka Mikulić, Nikolina Penava, Ivona Cvetković, Ante Pušić, Vinka Mikulić, Kristina Ljubić, Vajdana Tomić","doi":"10.11613/BM.2024.030701","DOIUrl":"10.11613/BM.2024.030701","url":null,"abstract":"<p><strong>Introduction: </strong>Ferroportin (Fpn) is the only known iron exporter and plays an essential role in iron homeostasis. Serum concentrations of Fpn in health and/or diseased states are still mostly unknown. Therefore, the aim of this study was to determine the concentration of Fpn in the serum of women of reproductive age (WRA) for the first time, and to establish whether there is a difference in the concentration of Fpn according to ferritin status.</p><p><strong>Materials and methods: </strong>This research included 100 WRA (18-45 years, C-reactive protein (CRP) < 5 mg/L, hemoglobin > 120 g/L). Serum Fpn was measured using Enzyme Linked Immunosorbent Assay (ELISA) method on the analyzer EZ Read 800 Plus (Biochrom, Cambridge, UK). Reference interval was calculated using the robust method.</p><p><strong>Results: </strong>The median concentration of Fpn in the whole study group was 9.74 (5.84-15.69) µg/L. The subgroup with ferritin concentration > 15 µg/L had a median Fpn concentration 15.21 (10.34-21.93) µg/L, which significantly differed from Fpn concentration in the subgroup with ferritin concentration ≤ 15 µg/L (5.93 (4.84-8.36) µg/L, P < 0.001). The reference limits for the Fpn were 2.26-29.81 µg/L with 90% confidence intervals (CI) of 1.78 to 2.83 and 25.37 to 34.33, respectively.</p><p><strong>Conclusions: </strong>The proposed reference interval could help in the future research on iron homeostasis both in physiological conditions and in various disorders, because this is the first study that measured Fpn concentration in a certain gender and age group of a healthy population.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
D-dimer assay interference detected by the discrepancy in D-dimer concentrations at different dilutions: a case report. 通过不同稀释度下 D-二聚体浓度的差异检测出 D-二聚体检测干扰:一份病例报告。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.031001
Marija Milić, Dejana Brkić Barbarić, Iva Lukić, Mirna Kirin, Vikica Buljanović, Vatroslav Šerić

This case report describes interference from heterophilic antibodies in D-dimer assay. The interference was suspected due to discrepancies between D-dimer concentrations in the original sample and diluted samples, as well as inconsistent clinical findings. The patient's medical history, laboratory results, and imaging studies were considered in the investigation. Heterophilic antibodies, likely developed during the SARS-CoV-2 infection, were identified as the probable cause of interference. The interference was confirmed through various methods, including dilution studies, blocking heterophilic antibodies, and comparing results with an alternative D-dimer method. This case highlights the importance of recognizing and addressing interference in D-dimer testing, emphasizing the need for collaboration between clinicians and laboratory specialists.

本病例报告描述了嗜异性抗体对 D-二聚体检测的干扰。怀疑干扰的原因是原始样本和稀释样本中的 D-二聚体浓度不一致,以及临床结果不一致。调查中考虑了患者的病史、实验室结果和影像学检查。嗜异性抗体可能是在 SARS-CoV-2 感染期间产生的,被确定为可能的干扰原因。干扰是通过各种方法确认的,包括稀释研究、阻断嗜异性抗体以及将结果与另一种 D-二聚体方法进行比较。这个病例突出了识别和处理 D-二聚体检测干扰的重要性,强调了临床医生和实验室专家合作的必要性。
{"title":"D-dimer assay interference detected by the discrepancy in D-dimer concentrations at different dilutions: a case report.","authors":"Marija Milić, Dejana Brkić Barbarić, Iva Lukić, Mirna Kirin, Vikica Buljanović, Vatroslav Šerić","doi":"10.11613/BM.2024.031001","DOIUrl":"10.11613/BM.2024.031001","url":null,"abstract":"<p><p>This case report describes interference from heterophilic antibodies in D-dimer assay. The interference was suspected due to discrepancies between D-dimer concentrations in the original sample and diluted samples, as well as inconsistent clinical findings. The patient's medical history, laboratory results, and imaging studies were considered in the investigation. Heterophilic antibodies, likely developed during the SARS-CoV-2 infection, were identified as the probable cause of interference. The interference was confirmed through various methods, including dilution studies, blocking heterophilic antibodies, and comparing results with an alternative D-dimer method. This case highlights the importance of recognizing and addressing interference in D-dimer testing, emphasizing the need for collaboration between clinicians and laboratory specialists.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory medicine and sports: where are we now? 实验室医学与运动:我们现在在哪里?
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030501
Lovorka Đerek, Vanja Radišić Biljak, Sanja Marević, Brankica Šimac, Marko Žarak, Antonija Perović, Domagoj Marijančević, Robert Buljubašić, Luka Matanović, Maja Cigrovski Berković

Laboratory medicine in sport and exercise has significantly developed during the last decades with the awareness that physical activity contributes to improved health status, and is present in monitoring both professional and recreational athletes. Training and competitions can modify concentrations of a variety of laboratory parameters, so the accurate laboratory data interpretation includes controlled and known preanalytical and analytical variables to prevent misleading interpretations. The paper represents a comprehensive summary of the lectures presented during the 35th Annual Symposium of the Croatian Society of Medical Biochemistry and Laboratory Medicine. It describes management of frequent sport injuries and sums up current knowledge of selected areas in laboratory medicine and sports including biological variation, changes in biochemical parameters and glycemic status. Additionally, the paper polemicizes sex hormone disorders in sports, encourages and comments research in recreational sports and laboratory medicine. In order to give the wider view, the connection of legal training protocols as well as monitoring prohibited substances in training is also considered through the eyes of laboratory medicine.

过去几十年来,随着人们认识到体育锻炼有助于改善健康状况,体育运动中的化验医学得到了长足的发展。训练和比赛会改变各种实验室参数的浓度,因此,准确的实验室数据解读包括可控和已知的分析前和分析变量,以防止误导性解读。本文全面总结了克罗地亚医学生物化学和实验室医学学会第 35 届年度研讨会上的演讲内容。论文介绍了常见运动损伤的处理方法,并总结了当前实验室医学和运动领域的部分知识,包括生物变异、生化参数变化和血糖状况。此外,论文还对运动中的性激素紊乱进行了论证,鼓励并评论了休闲运动和实验医学方面的研究。为了提供更广阔的视野,本文还从检验医学的角度探讨了合法训练规程与训练中违禁物质监测之间的联系。
{"title":"Laboratory medicine and sports: where are we now?","authors":"Lovorka Đerek, Vanja Radišić Biljak, Sanja Marević, Brankica Šimac, Marko Žarak, Antonija Perović, Domagoj Marijančević, Robert Buljubašić, Luka Matanović, Maja Cigrovski Berković","doi":"10.11613/BM.2024.030501","DOIUrl":"10.11613/BM.2024.030501","url":null,"abstract":"<p><p>Laboratory medicine in sport and exercise has significantly developed during the last decades with the awareness that physical activity contributes to improved health status, and is present in monitoring both professional and recreational athletes. Training and competitions can modify concentrations of a variety of laboratory parameters, so the accurate laboratory data interpretation includes controlled and known preanalytical and analytical variables to prevent misleading interpretations. The paper represents a comprehensive summary of the lectures presented during the 35<sup>th</sup> Annual Symposium of the Croatian Society of Medical Biochemistry and Laboratory Medicine. It describes management of frequent sport injuries and sums up current knowledge of selected areas in laboratory medicine and sports including biological variation, changes in biochemical parameters and glycemic status. Additionally, the paper polemicizes sex hormone disorders in sports, encourages and comments research in recreational sports and laboratory medicine. In order to give the wider view, the connection of legal training protocols as well as monitoring prohibited substances in training is also considered through the eyes of laboratory medicine.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative analysis of the color change in blue-green inclusions within neutrophils between two patients with different clinical outcomes. 对临床结果不同的两名患者中性粒细胞内蓝绿色包涵体颜色变化的比较分析。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030801
Junkun Chen, Ming Huang, Guo Li, Chi Zhang

Blue-green neutrophilic inclusions (BGNI), also known as "death bodies," are bright green structures observed in the cytoplasm of neutrophils or monocytes and are closely associated with acute liver failure, lactic acidosis, and other serious diseases. Some studies suggested a potential association with phagocytic lipofuscin released by damaged liver cells. The presence of BGNI typically indicated a poor prognosis. We presented two cases. Case 1 was diagnosed with novel bunyavirus infection and exhibited severe hepatic impairment and coagulation dysfunction along with the presence of BGNI in neutrophils. Despite receiving comprehensive symptomatic treatment, the patient's condition rapidly deteriorated leading to eventual demise. Case 2 had severe liver injury caused by wasp stings, and BGNI was observed. Following active treatment measures, the patient eventually achieved recovery. Throughout the disease course of case 1, there was a progressive deepening in color and increase in quantity of BGNI. Conversely, case 2 demonstrated an opposite trend. Based on the comparison of clinical outcomes and variations in color and quantity of BGNI between these two patients, it was found that an increase in the number and deepening of BGNI color corresponded to worsening condition. Conversely, a decrease in quantity and lightening of color indicated improvement. Hence, these findings suggest a possible association between changes in BGNI characteristics and prognosis.

蓝绿色嗜中性粒细胞包涵体(BGNI)又称 "死亡体",是在嗜中性粒细胞或单核细胞胞浆中观察到的亮绿色结构,与急性肝衰竭、乳酸酸中毒和其他严重疾病密切相关。一些研究表明,这可能与受损肝细胞释放的吞噬性脂褐素有关。出现 BGNI 通常预示着预后不良。我们介绍了两个病例。病例 1 被诊断为新型布尼亚病毒感染,表现出严重的肝功能损害和凝血功能障碍,中性粒细胞中也出现了 BGNI。尽管患者接受了全面的对症治疗,但病情迅速恶化,最终死亡。病例 2 因被马蜂蜇伤导致严重肝损伤,并观察到 BGNI。经过积极治疗,患者最终康复。在病例 1 的整个病程中,BGNI 的颜色逐渐加深,数量逐渐增多。相反,病例 2 则表现出相反的趋势。通过比较这两名患者的临床结果以及 BGNI 颜色和数量的变化,发现 BGNI 数量增加和颜色加深与病情恶化相对应。相反,数量减少和颜色变浅则表示病情好转。因此,这些研究结果表明,BGNI 特征的变化与预后之间可能存在关联。
{"title":"Comparative analysis of the color change in blue-green inclusions within neutrophils between two patients with different clinical outcomes.","authors":"Junkun Chen, Ming Huang, Guo Li, Chi Zhang","doi":"10.11613/BM.2024.030801","DOIUrl":"10.11613/BM.2024.030801","url":null,"abstract":"<p><p>Blue-green neutrophilic inclusions (BGNI), also known as \"death bodies,\" are bright green structures observed in the cytoplasm of neutrophils or monocytes and are closely associated with acute liver failure, lactic acidosis, and other serious diseases. Some studies suggested a potential association with phagocytic lipofuscin released by damaged liver cells. The presence of BGNI typically indicated a poor prognosis. We presented two cases. Case 1 was diagnosed with novel bunyavirus infection and exhibited severe hepatic impairment and coagulation dysfunction along with the presence of BGNI in neutrophils. Despite receiving comprehensive symptomatic treatment, the patient's condition rapidly deteriorated leading to eventual demise. Case 2 had severe liver injury caused by wasp stings, and BGNI was observed. Following active treatment measures, the patient eventually achieved recovery. Throughout the disease course of case 1, there was a progressive deepening in color and increase in quantity of BGNI. Conversely, case 2 demonstrated an opposite trend. Based on the comparison of clinical outcomes and variations in color and quantity of BGNI between these two patients, it was found that an increase in the number and deepening of BGNI color corresponded to worsening condition. Conversely, a decrease in quantity and lightening of color indicated improvement. Hence, these findings suggest a possible association between changes in BGNI characteristics and prognosis.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introducing prediction intervals for sample means. 引入样本均值的预测区间。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030101
Molly E Contini, Jeffrey R Spence, David J Stanley

Researchers and practitioners are typically familiar with descriptive statistics and statistical inference. However, outside of regression techniques, little attention may be given to questions around prediction. In the current paper, we introduce prediction intervals using fundamental concepts that are learned in descriptive and inferential statistical training (i.e., sampling error, standard deviation). We walk through an example using simple hand calculations and reference a simple R package that can be used to calculate prediction intervals.

研究人员和从业人员通常都熟悉描述性统计和统计推断。然而,在回归技术之外,人们可能很少关注与预测有关的问题。在本文中,我们使用描述性和推断性统计培训中学到的基本概念(即抽样误差、标准偏差)来介绍预测区间。我们用简单的手工计算举例说明,并参考了一个可用于计算预测区间的简单 R 软件包。
{"title":"Introducing prediction intervals for sample means.","authors":"Molly E Contini, Jeffrey R Spence, David J Stanley","doi":"10.11613/BM.2024.030101","DOIUrl":"10.11613/BM.2024.030101","url":null,"abstract":"<p><p>Researchers and practitioners are typically familiar with descriptive statistics and statistical inference. However, outside of regression techniques, little attention may be given to questions around prediction. In the current paper, we introduce prediction intervals using fundamental concepts that are learned in descriptive and inferential statistical training (<i>i.e.,</i> sampling error, standard deviation). We walk through an example using simple hand calculations and reference a simple R package that can be used to calculate prediction intervals.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The influence of calibration on bias in quality control and patient results for TSH on Vitros XT 7600 analyzer. 校准对 Vitros XT 7600 分析仪 TSH 质量控制和患者结果偏差的影响。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030703
Jill Boreyko, Josko Ivica

Introduction: Thyroid-stimulating hormone (TSH) is a glycoprotein secreted by the anterior pituitary gland and is regulated by negative feedback from the serum free thyroid hormones. In this study we aimed to quantitate the relative bias caused by calibration drifting as seen in our TSH Levey-Jennings quality control (QC) charts and assess the magnitude of bias on patients' samples.

Materials and methods: In the period from October 2021 to August 2022 we looked at the QC results of ten 28-days' calibration time intervals and calculated relative bias compared to the mean. For each time interval the mean from three QC points before and after calibration was calculated. The average from 10 pre- and post-calibration means was calculated and the relative bias, pre- and post-calibration, was then calculated. We used 5 patient samples with low, normal and high TSH concentrations and calculated relative bias pre- and post-calibration. The allowed relative bias for TSH is ± 6.7%.

Results: At both QC levels, with the respective means of 5.14 mIU/L (coefficient of variation, CV% = 3.1%) and 27.80 mIU/L (CV% = 3.2%) had their respective relative bias - 8.2% and - 7.9%. The patient samples with low (0.586 mIU/L), normal (2.89 mIU/L and 5.19 mIU/L) and high (20.5 mIU/L and 39.8 mIU/L) TSH had - 4.1%, - 4.0%, - 3.5%, - 5.1% and - 4.1%, respectively.

Conclusion: Even though the relative bias exceeded allowable criteria for the QC samples, this was not manifested on the patients' samples.

简介促甲状腺激素(TSH)是垂体前叶分泌的一种糖蛋白,受血清游离甲状腺激素的负反馈调节。在这项研究中,我们旨在量化 TSH Levey-Jennings 质量控制(QC)图表中校准漂移造成的相对偏差,并评估患者样本的偏差程度:在 2021 年 10 月至 2022 年 8 月期间,我们查看了 10 个 28 天校准时间间隔的质控结果,并计算了与平均值相比的相对偏差。对于每个时间间隔,计算校准前后三个质控点的平均值。计算校准前后 10 个平均值,然后计算校准前后的相对偏差。我们使用了 TSH 浓度较低、正常和较高的 5 份患者样本,并计算了校准前后的相对偏差。TSH 允许的相对偏差为 ± 6.7%:在两个质控水平上,平均值分别为 5.14 mIU/L(变异系数,CV% = 3.1%)和 27.80 mIU/L(CV% = 3.2%)的相对偏差分别为 - 8.2% 和 - 7.9%。低 TSH(0.586 mIU/L)、正常 TSH(2.89 mIU/L 和 5.19 mIU/L)和高 TSH(20.5 mIU/L 和 39.8 mIU/L)患者样本的相对偏差分别为-4.1%、-4.0%、-3.5%、-5.1%和-4.1%:尽管质控样本的相对偏差超过了允许的标准,但这在患者样本中并不明显。
{"title":"The influence of calibration on bias in quality control and patient results for TSH on Vitros XT 7600 analyzer.","authors":"Jill Boreyko, Josko Ivica","doi":"10.11613/BM.2024.030703","DOIUrl":"10.11613/BM.2024.030703","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid-stimulating hormone (TSH) is a glycoprotein secreted by the anterior pituitary gland and is regulated by negative feedback from the serum free thyroid hormones. In this study we aimed to quantitate the relative bias caused by calibration drifting as seen in our TSH Levey-Jennings quality control (QC) charts and assess the magnitude of bias on patients' samples.</p><p><strong>Materials and methods: </strong>In the period from October 2021 to August 2022 we looked at the QC results of ten 28-days' calibration time intervals and calculated relative bias compared to the mean. For each time interval the mean from three QC points before and after calibration was calculated. The average from 10 pre- and post-calibration means was calculated and the relative bias, pre- and post-calibration, was then calculated. We used 5 patient samples with low, normal and high TSH concentrations and calculated relative bias pre- and post-calibration. The allowed relative bias for TSH is ± 6.7%.</p><p><strong>Results: </strong>At both QC levels, with the respective means of 5.14 mIU/L (coefficient of variation, CV% = 3.1%) and 27.80 mIU/L (CV% = 3.2%) had their respective relative bias - 8.2% and - 7.9%. The patient samples with low (0.586 mIU/L), normal (2.89 mIU/L and 5.19 mIU/L) and high (20.5 mIU/L and 39.8 mIU/L) TSH had - 4.1%, - 4.0%, - 3.5%, - 5.1% and - 4.1%, respectively.</p><p><strong>Conclusion: </strong>Even though the relative bias exceeded allowable criteria for the QC samples, this was not manifested on the patients' samples.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of adrenocorticotropic hormone in whole blood samples: effects of storage conditions. 全血样本中促肾上腺皮质激素的稳定性:储存条件的影响。
Pub Date : 2024-10-15 Epub Date: 2024-08-05 DOI: 10.11613/BM.2024.030702
François Fraissinet, Hélène Girot, André Gillibert, Anaïs Melin, Julie Fettig, Valéry Brunel

Introduction: Adrenocorticotropic hormone (ACTH) is a peptide secreted by pituitary gland that plays an important role in regulating cortisol secretion. Its determination is difficult because of instability in whole blood. Several factors that influence ACTH stability in blood before analysis have been identified: temperature, hemolysis, time to centrifugation and presence of protease inhibitors. Published results on ACTH whole blood stability seem contradictory.

Materials and methods: We performed a stability study in 10 healthy volunteers. Three different conditions were tested: ethylenediaminetetraacetic acid (EDTA) at 4 °C, EDTA + aprotinin at 4 °C, EDTA + aprotinin at room temperature. Stability was evaluated for 8 hours. Adrenocorticotropic hormone measurements and hemolysis index were performed respectively on Cobas e602 and c701 (Roche Diagnostics, Mannheim, Germany). We compared percentage deviations with total change limit using a threshold of 7.5%.

Results: We showed that ACTH is stable 8 hours with EDTA at 4 °C, 4 hours with EDTA + aprotinin at 4 °C and 2 hours with EDTA + aprotinin at 22 °C.

Conclusions: Aprotinin does not appear to give ACTH greater stability but can be used without exceeding 4 hours at 4 °C. Refrigerated pouch transport also seems to be more appropriate for ACTH in whole blood.

简介促肾上腺皮质激素(ACTH)是垂体分泌的一种多肽,在调节皮质醇分泌方面发挥着重要作用。由于其在全血中不稳定,因此很难测定。目前已发现影响分析前 ACTH 在血液中稳定性的几个因素:温度、溶血、离心时间和蛋白酶抑制剂的存在。已发表的有关 ACTH 全血稳定性的结果似乎相互矛盾:我们对 10 名健康志愿者进行了稳定性研究。测试了三种不同的条件:乙二胺四乙酸(EDTA)4 °C、乙二胺四乙酸+阿普罗宁4 °C、乙二胺四乙酸+阿普罗宁室温。稳定性评估时间为 8 小时。肾上腺皮质激素测定和溶血指数测定分别在 Cobas e602 和 c701(罗氏诊断公司,德国曼海姆)上进行。我们以 7.5% 为临界值,比较了百分比偏差与总变化限度:结论:阿普罗汀似乎并不能提高促肾上腺皮质激素的稳定性,但在 4 °C 下使用不超过 4 小时也是可以的。冷藏袋运输似乎也更适合全血中的促肾上腺皮质激素。
{"title":"Stability of adrenocorticotropic hormone in whole blood samples: effects of storage conditions.","authors":"François Fraissinet, Hélène Girot, André Gillibert, Anaïs Melin, Julie Fettig, Valéry Brunel","doi":"10.11613/BM.2024.030702","DOIUrl":"10.11613/BM.2024.030702","url":null,"abstract":"<p><strong>Introduction: </strong>Adrenocorticotropic hormone (ACTH) is a peptide secreted by pituitary gland that plays an important role in regulating cortisol secretion. Its determination is difficult because of instability in whole blood. Several factors that influence ACTH stability in blood before analysis have been identified: temperature, hemolysis, time to centrifugation and presence of protease inhibitors. Published results on ACTH whole blood stability seem contradictory.</p><p><strong>Materials and methods: </strong>We performed a stability study in 10 healthy volunteers. Three different conditions were tested: ethylenediaminetetraacetic acid (EDTA) at 4 °C, EDTA + aprotinin at 4 °C, EDTA + aprotinin at room temperature. Stability was evaluated for 8 hours. Adrenocorticotropic hormone measurements and hemolysis index were performed respectively on Cobas e602 and c701 (Roche Diagnostics, Mannheim, Germany). We compared percentage deviations with total change limit using a threshold of 7.5%.</p><p><strong>Results: </strong>We showed that ACTH is stable 8 hours with EDTA at 4 °C, 4 hours with EDTA + aprotinin at 4 °C and 2 hours with EDTA + aprotinin at 22 °C.</p><p><strong>Conclusions: </strong>Aprotinin does not appear to give ACTH greater stability but can be used without exceeding 4 hours at 4 °C. Refrigerated pouch transport also seems to be more appropriate for ACTH in whole blood.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142020095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicles and glycans: new avenue for biomarker research. 细胞外囊泡和聚糖:生物标记研究的新途径。
Pub Date : 2024-06-15 DOI: 10.11613/BM.2024.020503
Tamara Janković, Miroslava Janković

The investigation of biomarkers is constantly evolving. New molecules and molecular assemblies, such as soluble and particulate complexes, emerged as biomarkers from basic research and investigation of different proteomes, genomes, and glycomes. Extracellular vesicles (EVs), and glycans, complex carbohydrates are ubiquitous in nature. The composition and structure of both reflect physiological state of paternal cells and are strikingly changed in diseases. The EV-associated glycans, alone or in combination with soluble glycans in related biological fluids, used as analytes, aim to capture full complex biomarker picture, enabling its use in different clinical settings. Bringing together EVs and glycans can help to extract meaningful data from their extreme and distinct heterogeneities for use in the real-time diagnostics. The glycans on the surface of EVs could mark their subpopulations and establish the glycosignature, the solubilisation signature and molecular patterns. They all contribute to a new way of looking at and looking for composite biomarkers.

生物标记物的研究在不断发展。通过对不同蛋白质组、基因组和糖蛋白的基础研究和调查,出现了新的分子和分子组合,如可溶性和颗粒状复合物,可作为生物标记物。细胞外囊泡(EV)和聚糖(复杂的碳水化合物)在自然界中无处不在。二者的组成和结构反映了父系细胞的生理状态,并在疾病中发生显著变化。EV 相关聚糖单独或与相关生物液体中的可溶性聚糖结合用作分析物,旨在捕捉复杂的生物标记全貌,使其能用于不同的临床环境。将 EV 和聚糖结合起来,有助于从它们极端而独特的异质性中提取有意义的数据,用于实时诊断。EVs 表面的聚糖可以标记其亚群,并建立糖特征、溶解特征和分子模式。它们都有助于以一种新的方式来观察和寻找复合生物标记物。
{"title":"Extracellular vesicles and glycans: new avenue for biomarker research.","authors":"Tamara Janković, Miroslava Janković","doi":"10.11613/BM.2024.020503","DOIUrl":"10.11613/BM.2024.020503","url":null,"abstract":"<p><p>The investigation of biomarkers is constantly evolving. New molecules and molecular assemblies, such as soluble and particulate complexes, emerged as biomarkers from basic research and investigation of different proteomes, genomes, and glycomes. Extracellular vesicles (EVs), and glycans, complex carbohydrates are ubiquitous in nature. The composition and structure of both reflect physiological state of paternal cells and are strikingly changed in diseases. The EV-associated glycans, alone or in combination with soluble glycans in related biological fluids, used as analytes, aim to capture full complex biomarker picture, enabling its use in different clinical settings. Bringing together EVs and glycans can help to extract meaningful data from their extreme and distinct heterogeneities for use in the real-time diagnostics. The glycans on the surface of EVs could mark their subpopulations and establish the glycosignature, the solubilisation signature and molecular patterns. They all contribute to a new way of looking at and looking for composite biomarkers.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiphospholipid antibodies in patients with antiphospholipid syndrome. 抗磷脂综合征患者的抗磷脂抗体。
Pub Date : 2024-06-15 DOI: 10.11613/BM.2024.020504
Slavica Dodig, Ivana Čepelak

Antiphospholipid syndrome (APS) is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies (aPLs) in plasma/serum. Antiphospholipid antibodies are a heterogeneous, overlapping group of autoantibodies, of which anti-β2-glycoprotein I (aβ2GPI), anticardiolipin (aCL) antibodies and antibodies that prolong plasma clotting time in tests in vitro known as lupus anticoagulant (LAC) are included in the laboratory criteria for the diagnosis of APS. The presence of LAC antibodies in plasma is indirectly determined by measuring the length of coagulation in two tests - activated partial thromboplastin time (aPTT) and diluted Russell's viper venom time (dRVVT). The concentration of aβ2GPI and aCL (immunglobulin G (IgG) and immunoglobulin M (IgM) isotypes) in serum is directly determined by solid-phase immunoassays, either by enzyme-linked immunosorbent assay (ELISA), fluoroimmunoassay (FIA), immunochemiluminescence (CLIA) or multiplex flow immunoassay (MFIA). For patient safety, it is extremely important to control all three phases of laboratory testing, i.e. preanalytical, analytical and postanalytical phase. Specialists in laboratory medicine must be aware of interferences in all three phases of laboratory testing, in order to minimize these interferences. The aim of this review was to show the current pathophysiological aspects of APS, the importance of determining aPLs-a in plasma/serum, with an emphasis on possible interferences that should be taken into account when interpreting laboratory findings.

抗磷脂综合征(APS)是一种罕见的全身性自身免疫性疾病,其特点是妊娠期反复发病或血栓形成,同时血浆/血清中持续存在抗磷脂抗体(aPL)。抗磷脂抗体是一组异质、重叠的自身抗体,其中抗β2-糖蛋白I(aβ2GPI)抗体、抗心磷脂(aCL)抗体和在体外测试中延长血浆凝固时间的抗体(称为狼疮抗凝物(LAC))被列入诊断APS的实验室标准。通过活化部分凝血活酶时间(aPTT)和稀释罗素蝰蛇毒时间(dRVVT)这两项测试来测量凝血时间的长短,从而间接确定血浆中是否存在 LAC 抗体。血清中 aβ2GPI 和 aCL(免疫球蛋白 G (IgG) 和免疫球蛋白 M (IgM)异型)的浓度可通过固相免疫测定法(酶联免疫吸附法 (ELISA)、荧光免疫测定法 (FIA)、免疫化学发光法 (CLIA) 或多重流式免疫测定法 (MFIA))直接测定。为了患者的安全,对实验室检测的所有三个阶段,即分析前、分析中和分析后阶段进行控制极为重要。实验室医学专家必须了解实验室检测所有三个阶段的干扰,以便将这些干扰降至最低。本综述旨在说明目前 APS 的病理生理学方面、测定血浆/血清中 aPLs-a 的重要性,重点是在解释实验室结果时应考虑的可能干扰。
{"title":"Antiphospholipid antibodies in patients with antiphospholipid syndrome.","authors":"Slavica Dodig, Ivana Čepelak","doi":"10.11613/BM.2024.020504","DOIUrl":"10.11613/BM.2024.020504","url":null,"abstract":"<p><p>Antiphospholipid syndrome (APS) is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies (aPLs) in plasma/serum. Antiphospholipid antibodies are a heterogeneous, overlapping group of autoantibodies, of which anti-β2-glycoprotein I (aβ2GPI), anticardiolipin (aCL) antibodies and antibodies that prolong plasma clotting time in tests <i>in vitro</i> known as lupus anticoagulant (LAC) are included in the laboratory criteria for the diagnosis of APS. The presence of LAC antibodies in plasma is indirectly determined by measuring the length of coagulation in two tests - activated partial thromboplastin time (aPTT) and diluted Russell's viper venom time (dRVVT). The concentration of aβ2GPI and aCL (immunglobulin G (IgG) and immunoglobulin M (IgM) isotypes) in serum is directly determined by solid-phase immunoassays, either by enzyme-linked immunosorbent assay (ELISA), fluoroimmunoassay (FIA), immunochemiluminescence (CLIA) or multiplex flow immunoassay (MFIA). For patient safety, it is extremely important to control all three phases of laboratory testing, <i>i.e.</i> preanalytical, analytical and postanalytical phase. Specialists in laboratory medicine must be aware of interferences in all three phases of laboratory testing, in order to minimize these interferences. The aim of this review was to show the current pathophysiological aspects of APS, the importance of determining aPLs-a in plasma/serum, with an emphasis on possible interferences that should be taken into account when interpreting laboratory findings.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement. 循环 microRNA 测量中的分析前、分析中和分析后注意事项。
Pub Date : 2024-06-15 DOI: 10.11613/BM.2024.020501
Mustapha Zendjabil

Microribonucleic acids (miRNAs) have emerged as a new category of biomarkers for many human diseases like cancer, cardiovascular and neurodegenerative disorders. MicroRNAs can be detected in various body fluids including blood, urine and cerebrospinal fluid. However, the literature contains conflicting results for circulating miRNAs, which is the main barrier to using miRNAs as non-invasive biomarkers. This variability in results is largely due to differences between studies in sample processing methodology, miRNA quantification and result normalization. The purpose of this review is to describe the various preanalytical, analytical and postanalytical factors that can impact miRNA detection accuracy and to propose recommendations for the standardization of circulating miRNAs measurement.

微核糖核酸(miRNA)已成为癌症、心血管疾病和神经退行性疾病等多种人类疾病的新型生物标志物。在血液、尿液和脑脊液等各种体液中都能检测到微小核糖核酸。然而,文献中关于循环 miRNA 的研究结果相互矛盾,这是使用 miRNA 作为非侵入性生物标记物的主要障碍。结果的差异主要是由于不同研究在样本处理方法、miRNA 定量和结果归一化方面存在差异。本综述旨在描述可能影响 miRNA 检测准确性的各种分析前、分析中和分析后因素,并就循环 miRNA 测量的标准化提出建议。
{"title":"Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement.","authors":"Mustapha Zendjabil","doi":"10.11613/BM.2024.020501","DOIUrl":"10.11613/BM.2024.020501","url":null,"abstract":"<p><p>Microribonucleic acids (miRNAs) have emerged as a new category of biomarkers for many human diseases like cancer, cardiovascular and neurodegenerative disorders. MicroRNAs can be detected in various body fluids including blood, urine and cerebrospinal fluid. However, the literature contains conflicting results for circulating miRNAs, which is the main barrier to using miRNAs as non-invasive biomarkers. This variability in results is largely due to differences between studies in sample processing methodology, miRNA quantification and result normalization. The purpose of this review is to describe the various preanalytical, analytical and postanalytical factors that can impact miRNA detection accuracy and to propose recommendations for the standardization of circulating miRNAs measurement.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biochemia medica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1